109 related articles for article (PubMed ID: 28105615)
21. [Impacts of microsatellite status, RAS and BRAF mutation on postoperative follow-up strategy in stage II( and III( colorectal cancer].
Zhang J; Wang X; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Jun; 21(6):716-720. PubMed ID: 29968248
[TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
23. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
[TBL] [Abstract][Full Text] [Related]
24. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
Amin MB; Greene FL; Edge SB; Compton CC; Gershenwald JE; Brookland RK; Meyer L; Gress DM; Byrd DR; Winchester DP
CA Cancer J Clin; 2017 Mar; 67(2):93-99. PubMed ID: 28094848
[TBL] [Abstract][Full Text] [Related]
25. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].
Lai M
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564
[No Abstract] [Full Text] [Related]
26. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
27. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer.
Karadima ML; Saetta AA; Chatziandreou I; Lazaris AC; Patsouris E; Tsavaris N
Pathol Oncol Res; 2016 Oct; 22(4):707-14. PubMed ID: 27033063
[TBL] [Abstract][Full Text] [Related]
29. Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis.
Aoyagi H; Iida S; Uetake H; Ishikawa T; Takagi Y; Kobayashi H; Higuchi T; Yasuno M; Enomoto M; Sugihara K
Oncol Rep; 2011 Mar; 25(3):789-94. PubMed ID: 21174064
[TBL] [Abstract][Full Text] [Related]
30. Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer.
Li L; Ni BB; Zhong QH; Liu YH; Zhang MH; Zhang KP; Chen DC; Wang L
Future Oncol; 2017 Jul; 13(17):1473-1492. PubMed ID: 28685592
[TBL] [Abstract][Full Text] [Related]
31. Analysis of factors influencing molecular testing at diagnostic of colorectal cancer.
Thiebault Q; Defossez G; Karayan-Tapon L; Ingrand P; Silvain C; Tougeron D
BMC Cancer; 2017 Nov; 17(1):765. PubMed ID: 29137623
[TBL] [Abstract][Full Text] [Related]
32. Use of a High-Throughput Genotyping Platform (OncoMap) for
Kim D; Hong YS; Kim JE; Kim KP; Lee JL; Chun SM; Kim J; Jang SJ; Kim TW
Cancer Res Treat; 2017 Jan; 49(1):37-43. PubMed ID: 27121720
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
34. Annexin A10 expression in colorectal cancers with emphasis on the serrated neoplasia pathway.
Bae JM; Kim JH; Rhee YY; Cho NY; Kim TY; Kang GH
World J Gastroenterol; 2015 Sep; 21(33):9749-57. PubMed ID: 26361422
[TBL] [Abstract][Full Text] [Related]
35. Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.
Amaki-Takao M; Yamaguchi T; Natsume S; Iijima T; Wakaume R; Takahashi K; Matsumoto H; Miyaki M
Oncology; 2016; 91(3):162-70. PubMed ID: 27404270
[TBL] [Abstract][Full Text] [Related]
36. NDRG4 stratifies the prognostic value of body mass index in colorectal cancer.
Zheng J; Li Y; Zhu S; Li J; Zhao Q; Ji G; Wang W; Chu D
Oncotarget; 2016 Jan; 7(2):1311-22. PubMed ID: 26515606
[TBL] [Abstract][Full Text] [Related]
37. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
39. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
